oa South African Family Practice - Patients who switched from established Lipitor therapy to simvastatin experienced a significant 30 percent increase in relative risk of cardiovascular events or death, new observational study shows : press release

Volume 49, Issue 10
  • ISSN : 2078-6190
  • E-ISSN: 2078-6204



Vienna, Austria, September 5 - An observational study of a large United Kingdom primary care database showed that switching patients from Pfizer's Lipitor(R) (atorvastatin calcium) Tablets to simvastatin was associated with a 30 percent increase in the relative risk of major cardiovascular events, including heart attacks, strokes and certain types of heart surgeries, or death compared to patients who remained on Lipitor therapy.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error